Innovent eyes third-line nod for gastric cancer ADC on Phase III PFS hit

Innovent's Gastric Cancer ADC Hits Phase III PFS Endpoint, NMPA Grants Priority Review

Innovent Biologics' CLDN18.2-targeting antibody-drug conjugate, arcotatug tavatecan, achieved its primary endpoint of significantly boosting progression-free survival (PFS) in the Phase III G-HOPE-001 study. The trial evaluated the drug as a third-line therapy for refractory, locally advanced, unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma (G/GEJA) in China and Japan. Following these positive results, China's National Medical Products Administration (NMPA) has accepted Innovent's new drug application (NDA) for arcotatug tavatecan under priority review, aiming for it to be the first CLDN18.2-targeting ADC approved in this setting.

• The Phase III G-HOPE-001 study demonstrated that arcotatug tavatecan provided a significant boost to progression-free survival (PFS) in third-line-plus patients with CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma. The drug also exhibited a manageable safety profile, offering a potential new treatment option for patients with limited choices and poor prognosis in this challenging setting.
• China's National Medical Products Administration (NMPA) has accepted Innovent's new drug application for arcotatug tavatecan under priority review for third-line, CLDN18.2-positive G/GEJA. If approved, it would become the first CLDN18.2-targeting ADC to receive regulatory approval, addressing a significant unmet need given that CLDN18.2 is highly expressed in a substantial proportion of these tumors.
• Arcotatug tavatecan is designed as a precision medicine, selectively delivering a high-potency exatecan payload to tumor cells while minimizing off-tumor toxicities. This development is also significant for Takeda, which previously secured the rights to the ADC outside of China through an $11.4 billion mega-deal in October 2025, highlighting the asset's global strategic value.

Arcotatug Tavatecan: A New Frontier in G/GEJA Treatment

The treatment landscape for gastric and gastroesophageal junction adenocarcinoma has undergone significant transformation over the past five years, driven primarily by advances in targeted therapies and precision medicine approaches. CLDN18.2 has emerged as a major new therapeutic target, with 143 clinical trials identified and a marked increase in development since 2021. The approval of zolbetuximab has opened new pathways for precision treatment, while drug development encompasses monoclonal antibodies (32.17%), antibody-drug conjugates (26.57%), and CAR-T therapies (23.08%). HER2-targeted therapy has achieved substantial advancements, exemplified by the KC-WISE trial demonstrating that anbenitamab plus chemotherapy significantly improved progression-free survival (median 7.1 vs 2.7 months; HR 0.25; p<0.0001) and overall survival (median 19.6 vs 11.5 months; HR 0.29; p<0.0001) in HER2-positive patients after trastuzumab failure. Additional research continues on emerging targets including FGFR2b, MET, DKK1, and TROP2, aiming to offer personalized treatment strategies.

Perioperative and neoadjuvant approaches have gained prominence through landmark phase III studies PRODIGY and RESOLVE, which established neoadjuvant chemotherapy as a viable therapeutic option in Asia for locally advanced gastric cancer. The MATTERHORN trial demonstrated the potential of incorporating immune checkpoint inhibitors into perioperative treatment paradigms. However, key challenges remain, including the unclear validity of pathological response as a surrogate endpoint for survival, the need for risk- and biomarker-driven patient selection, and unresolved questions regarding the necessity and optimal duration of postoperative therapy. Immunotherapy has shown promise with agents like sugemalimab plus CAPOX demonstrating significant improvements in overall survival (median 15.6 vs 12.6 months; HR 0.75; p=0.006) in patients with PD-L1 CPS ≥5, though benefits are limited to specific patient subsets rather than the entire population.

Despite these advances, significant challenges persist in translating molecular insights into clinical benefit. A meta-analysis of eight phase III trials involving 4,223 patients from 2016-2020 revealed that overall and progression-free survival of molecular and conventional therapy were comparable, with most trials showing no significant differences in tumor response rates or severe adverse effects. Only three molecular therapy agents have received FDA approval for advanced gastric cancer, with survival benefits remaining unclear due to inaccurate patient selection, particularly regarding oncogene amplification and copy number variations. The COVID-19 pandemic has further complicated the landscape, with studies showing increased metastatic presentation at diagnosis (64.4% vs 42.8% pre-pandemic) and delayed diagnosis leading to stage migration toward advanced disease. These findings underscore the critical need for improved biomarker-driven patient selection and the development of more effective therapeutic strategies that can consistently deliver meaningful clinical outcomes.

Addressing Unmet Needs in Refractory CLDN18.2+ G/GEJA

Current treatment approaches for gastric and gastroesophageal junction adenocarcinoma face significant challenges that continue to limit patient outcomes. These limitations span from diagnostic delays and treatment resistance to the complex genetic heterogeneity that characterizes this malignancy. The field urgently requires more precise, molecularly-driven therapeutic strategies to address these persistent gaps.

• Late-stage diagnosis and poor prognosis: Most gastric malignancies are diagnosed at an advanced stage and are associated with a grim prognosis, with outcomes in Western countries remaining particularly poor due to advanced disease at presentation

• Limited efficacy of traditional approaches: Traditional therapeutic strategies have failed to significantly improve survival in patients with advanced gastric cancer, and without curative surgery, variations and combinations of chemotherapy and/or radiation cannot bring clinically meaningful success

• Genetic complexity and heterogeneity: Progress in gastric cancer treatment has been limited primarily due to the disease's genetic complexity and heterogeneity, making it difficult to develop universally effective targeted therapies

• Inadequate post-surgical outcomes: Even after multimodal therapies following curative surgery, the prognosis of most advanced cancer patients requires improvement, with gastric adenocarcinoma survivors showing declining relative survival from 97.3% at year 6 to 86.6% at year 10

• Resistance to targeted therapies: Many patients with metastatic gastric cancer who receive trastuzumab in combination with chemotherapeutic agents develop resistance to the targeted therapy, limiting long-term treatment effectiveness

• Limited applicability of targeted agents: The majority of gastric cancer patients do not harbor ERBB2 (HER2) amplification and thus cannot benefit from targeted therapy under current practice paradigms, while effective therapy for KRAS-driven gastric cancer has not been established

• Failed translation from other malignancies: Many clinical trials testing novel molecular targeted agents with demonstrated efficacy in other malignancies have failed to show benefit in patients with metastatic gastric cancer, highlighting the need for disease-specific biomarker selection

• Acquired resistance mechanisms: Prolonged MAPK pathway inhibition can result in acquired resistance associated with increased malignant phenotype in KRAS mutant gastric cancer, limiting the durability of pathway-targeted approaches

G-HOPE-001: Arcotatug Tavatecan's Efficacy and Safety Profile

Recent clinical studies have demonstrated significant advances in gastric and gastroesophageal junction adenocarcinoma treatment across multiple therapeutic approaches. These trials span from early-phase dose-escalation studies to large randomized controlled trials, providing comprehensive data on both targeted therapies and immunotherapies in various patient populations.

The Expanding Landscape of CLDN18.2-Targeted Therapies

Several anti-CLDN18.2 antibody-drug conjugates (ADCs) are advancing through late-stage clinical development for CLDN18.2-positive gastric or gastroesophageal junction adenocarcinomas, representing a competitive therapeutic landscape. All identified compounds share the same mechanism of action as arcotatug tavatecan, targeting the CLDN18.2 protein through ADC technology. However, specific intervention model details for these trials were not available in the literature reviewed.

Pioneering CLDN18.2 ADC Targets Refractory G/GEJA

The recent positive Phase III results for Innovent Biologics' arcotatug tavatecan represent a pivotal moment in the treatment of refractory CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma (G/GEJA). For patients facing this aggressive cancer in the third-line setting, where options are severely limited, the prospect of a new, effective targeted therapy is significant. This antibody-drug conjugate (ADC) has demonstrated a meaningful improvement in progression-free survival, underscoring the therapeutic potential of targeting CLDN18.2 with this advanced modality.

Innovent's strategic move to secure priority review in China positions arcotatug tavatecan to potentially become the first CLDN18.2-targeting ADC approved globally. This first-mover advantage could be instrumental in establishing a strong foothold in the rapidly evolving CLDN18.2 landscape, particularly within the substantial markets of China and Japan. The success also validates the broader ADC platform for CLDN18.2, likely encouraging further investment and development in this class of drugs.

However, the path forward is not without its complexities. The CLDN18.2 space is intensely competitive, with a robust pipeline of other ADCs, such as IBI343, AZD0901, and LM-302, alongside monoclonal antibodies like zolbetuximab, all vying for market share across different lines of therapy. This competitive pressure necessitates strong differentiation and robust clinical data. Furthermore, while ADCs offer promising efficacy, their safety profiles, including potential dose-limiting toxicities like myelosuppression, will be under close scrutiny. Understanding the optimal sequencing of CLDN18.2-targeting therapies and refining biomarker strategies for patient selection will be critical for maximizing clinical benefit and market penetration. The emergence of longitudinal companion diagnostics will also play a key role in guiding treatment decisions. As the field matures, the interplay between various CLDN18.2 modalities—from ADCs to bispecific antibodies and CAR T-cells—will define the future treatment paradigm for G/GEJA and other CLDN18.2-positive solid tumors.